设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH研究的应用及单片复方制剂(SPC)在高血压治疗中的地位--Weber教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:ACCOMPLISH 单片复方制剂 倍博特 阿利吉仑 


International Circulation:  What impact will the ACCOMPLISH study have on recommendation of SPC in the JNC8 and ESC/ESH hypertension guidelines?

国际循环:ACCOMPLISH研究将对JNC8和ESC/ESH高血压指南中的SPC推荐产生什么影响?

Michael Weber:  The ACCOMPLISH study is going to be very supportive of the guidelines both in the United States and in Europe, and I suspect around the world, because more and more, not just guidelines but even regulatory agencies such as the Food and Drug Administration in the United States, are approving the use of fixed dose, two drug combinations as first-line treatment for the management of hypertension.  ACCOMPLISH really gives more fuel to that decision and really emphasizes how efficient it is to use that sort of approach. 

Michael Weber教授:ACCOMPLISH研究影响了美国、欧洲、甚至是世界的指南,因为更多的指南、甚至如美国食品和药物监督管理局等宏观调控机构都开始赞同将固定剂量、双药联合疗法作为降压一线疗法。ACCOMPLISH试验结果进一步促成了此决定的下达,并突显了该疗法的有效性。



上一页  [1]  [2]  [3]  [4]  [5]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved